Merck ROA 2010-2022 | MRK

Current and historical return on assets (ROA) values for Merck (MRK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Merck ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $16.58B $107.10B 16.06%
2022-03-31 $14.18B $106.67B 14.30%
2021-12-31 $13.05B $105.69B 13.71%
2021-09-30 $7.20B $93.49B 7.85%
2021-06-30 $5.57B $90.69B 6.14%
2021-03-31 $7.03B $90.85B 7.75%
2020-12-31 $7.07B $91.59B 7.92%
2020-09-30 $11.52B $89.80B 13.17%
2020-06-30 $10.48B $90.62B 12.21%
2020-03-31 $10.15B $84.91B 12.06%
2019-12-31 $9.84B $84.40B 11.79%
2019-09-30 $9.31B $83.33B 11.21%
2019-06-30 $9.36B $83.97B 11.21%
2019-03-31 $8.40B $82.35B 10.02%
2018-12-31 $6.22B $82.64B 7.34%
2018-09-30 $3.35B $85.13B 3.89%
2018-06-30 $1.34B $85.04B 1.53%
2018-03-31 $1.58B $86.04B 1.76%
2017-12-31 $2.39B $87.87B 2.60%
2017-09-30 $2.85B $91.68B 3.03%
2017-06-30 $5.09B $92.80B 5.31%
2017-03-31 $4.35B $96.56B 4.49%
2016-12-31 $3.92B $95.38B 4.03%
2016-09-30 $5.49B $98.34B 5.56%
2016-06-30 $5.13B $96.48B 5.16%
2016-03-31 $4.61B $98.76B 4.57%
2015-12-31 $4.44B $101.68B 4.29%
2015-09-30 $10.78B $101.23B 10.51%
2015-06-30 $9.85B $102.58B 9.59%
2015-03-31 $11.17B $108.35B 11.00%
2014-12-31 $11.92B $98.17B 11.74%
2014-09-30 $5.39B $101.81B 5.21%
2014-06-30 $5.61B $97.86B 5.37%
2014-03-31 $4.52B $108.46B 4.23%
2013-12-31 $4.40B $105.65B 4.14%
2013-09-30 $4.53B $106.42B 4.26%
2013-06-30 $5.14B $106.88B 4.83%
2013-03-31 $6.02B $106.20B 5.68%
2012-12-31 $6.17B $106.13B 5.82%
2012-09-30 $6.76B $106.30B 6.40%
2012-06-30 $6.72B $105.53B 6.36%
2012-03-31 $6.95B $105.51B 6.57%
2011-12-31 $6.26B $105.13B 5.91%
2011-09-30 $4.22B $106.53B 3.98%
2011-06-30 $2.87B $106.20B 2.70%
2011-03-31 $1.60B $105.87B 1.51%
2010-12-31 $0.86B $105.78B 0.80%
2010-09-30 $7.84B $107.84B 7.16%
2010-06-30 $10.92B $106.17B 11.53%
2010-03-31 $11.73B $111.59B 14.56%
2009-12-31 $12.85B $112.31B 20.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.318B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17